Specialty trend reached $62.25 PMPM (+11.1%), largely from utilization growth in oncology, immunology, and dermatology; ...
The therapies are incredible, says Will Shrank, M.D. They can “totally transform the lives of those who can benefit.” But ...
Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the ...
Machine-learning aging clocks built from proteins, metabolites, and imaging estimated organ-specific biological aging, enabling cross-validation of sleep associations across multi-omics layers. A ...
Levitt said KFF polling suggests patient frustration with prior authorization remains widespread across employer-sponsored ...
Bispecific antibodies could mean simpler regimens that will require fewer clinic visits, Adams said. She also mentioned the possibility of fixed-duration therapy and patients getting to the status of ...
After step-up dosing, treatment with bispecific antibodies does not require the use of steroids, Adams noted, so patients are spared steroid side effects. Bispecific antibody treatment advances could ...
Cross-sectional secondary analyses used SF-36 pain interference responses and medical-record diagnoses to operationalize “undiagnosed pain” as activity-limiting pain without documented pain conditions ...
Phase 3 interim results at 72 weeks showed semaglutide plus lifestyle achieved MASH resolution without fibrosis worsening in 63% versus 34% with placebo plus lifestyle. Preclinical MASH models ...
Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results